Propagation of organoids from urology tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030035

Enrollment

100

Registered

2022-09-13

Start date

2022-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma, renal cancer, prostata cancer, penile cancer C60 C61 C64 C65 C66 C67 C68

Interventions

Group 1: Organoids will be derived from metastases of urology tumors. After biopsy, a small part of the metastasis that is not relevant for the routine diagnostic procedure will be propagated to organ

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Informed consent of the patient

Exclusion criteria

Exclusion criteria: Decline by the patient

Design outcomes

Primary

Measure	Time frame
The primary outcome is the propagation of organoids from metastatic tumors per se.	—

Secondary

Measure	Time frame
Secondary endpoints include proteome-, genome-, transcriptome-, epigenome- analysis as well as compound testings on the organoids.	—

Countries

Germany

Contacts

Public ContactMichael Melzer

Universitätsklinikum Ulm, Klinik für Urologie und Kinderurologie

michael.melzer@uniklinik-ulm.de073150058000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026